Rakovina Presents Preclinical Data at the 2022 AACR Special Conference on Sarcomas
Rakovina highlighted the development of its kt-3000 drug candidates as a potential treatment of Ewing sarcoma and other soft tissue tutors..
© 2023 Frontier Merchant Capital Group. All Rights Reserved.